These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 7871061)

  • 1. MAO inhibitors in panic disorder: clinical effects of treatment with brofaromine. A double blind placebo controlled study.
    van Vliet IM; Westenberg HG; Den Boer JA
    Psychopharmacology (Berl); 1993; 112(4):483-9. PubMed ID: 7871061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brofaromine in panic disorder: a pilot study with a new reversible inhibitor of monoamine oxidase-A.
    Garcia-Borreguero D; Lauer CJ; Ozdaglar A; Wiedemann K; Holsboer F; Krieg JC
    Pharmacopsychiatry; 1992 Nov; 25(6):261-4. PubMed ID: 1494591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversible monoamine oxidase-A inhibitors in panic disorder.
    Bakish D; Saxena BM; Bowen R; D'Souza J
    Clin Neuropharmacol; 1993; 16 Suppl 2():S77-82. PubMed ID: 8313401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-blind comparative study of brofaromine and fluvoxamine in outpatients with panic disorder.
    van Vliet IM; den Boer JA; Westenberg HG; Slaap BR
    J Clin Psychopharmacol; 1996 Aug; 16(4):299-306. PubMed ID: 8835705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor.
    van Vliet IM; den Boer JA; Westenberg HG
    Eur Neuropsychopharmacol; 1992 Mar; 2(1):21-9. PubMed ID: 1638170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of the reversible monoamine oxidase-A inhibitor brofaromine in social phobia complicated by panic disorder with or without agoraphobia.
    Bakish D
    J Clin Psychopharmacol; 1994 Feb; 14(1):74-5. PubMed ID: 8151007
    [No Abstract]   [Full Text] [Related]  

  • 7. Social phobia: the clinical efficacy and tolerability of the monoamine oxidase -A and serotonin uptake inhibitor brofaromine. A double-blind placebo-controlled study.
    Fahlén T; Nilsson HL; Borg K; Humble M; Pauli U
    Acta Psychiatr Scand; 1995 Nov; 92(5):351-8. PubMed ID: 8619339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brofaromine in depression: a Canadian multicenter placebo trial and a review of standard drug comparative studies.
    Chouinard G; Saxena BM; Nair NP; Kutcher SP; Bakish D; Bradwejn J; Kennedy SH; Sharma V; Remick RA; Kukha-Mohamad SA
    Clin Neuropharmacol; 1993; 16 Suppl 2():S51-4. PubMed ID: 8313397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoamine oxidase inhibitors in resistant major depression. A double-blind comparison of brofaromine and tranylcypromine in patients resistant to tricyclic antidepressants.
    Nolen WA; Haffmans PM; Bouvy PF; Duivenvoorden HJ
    J Affect Disord; 1993 Jul; 28(3):189-97. PubMed ID: 8408980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversible monoamine-A inhibitors in panic disorder.
    Bakish D
    Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():432A-433A. PubMed ID: 1498904
    [No Abstract]   [Full Text] [Related]  

  • 11. Phobic symptoms as predictors of nonresponse to drug therapy in panic disorder patients (a preliminary report).
    Slaap BR; van Vliet IM; Westenberg HG; den Boer JA
    J Affect Disord; 1995 Jan; 33(1):31-8. PubMed ID: 7714306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical, biochemical and psychometric findings with the new MAO-A-inhibitors moclobemide and brofaromine in patients with major depressive disorder.
    Laux G; Classen W; Sofic E; Becker T; Riederer P; Lesch KP; Struck M; Beckmann H
    J Neural Transm Suppl; 1990; 32():189-95. PubMed ID: 2089089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, safety, and gradual discontinuation of clonazepam in panic disorder: a placebo-controlled, multicenter study using optimized dosages.
    Moroz G; Rosenbaum JF
    J Clin Psychiatry; 1999 Sep; 60(9):604-12. PubMed ID: 10520979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder.
    Ballenger JC; Wheadon DE; Steiner M; Bushnell W; Gergel IP
    Am J Psychiatry; 1998 Jan; 155(1):36-42. PubMed ID: 9433336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder.
    Pollack MH; Lepola U; Koponen H; Simon NM; Worthington JJ; Emilien G; Tzanis E; Salinas E; Whitaker T; Gao B
    Depress Anxiety; 2007; 24(1):1-14. PubMed ID: 16894619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic and side-effect profile of a selective and reversible MAO-A inhibitor, brofaromine. Results of dose-finding trials in depressed patients.
    Schiwy W; Heath WR; Delini-Stula A
    J Neural Transm Suppl; 1989; 28():33-44. PubMed ID: 2677240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is there a role for selective monoamine oxidase inhibitor therapy in bulimia nervosa? A placebo-controlled trial of brofaromine.
    Kennedy SH; Goldbloom DS; Ralevski E; Davis C; D'Souza JD; Lofchy J
    J Clin Psychopharmacol; 1993 Dec; 13(6):415-22. PubMed ID: 8120155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brofaromine for social phobia: a multicenter, placebo-controlled, double-blind study.
    Lott M; Greist JH; Jefferson JW; Kobak KA; Katzelnick DJ; Katz RJ; Schaettle SC
    J Clin Psychopharmacol; 1997 Aug; 17(4):255-60. PubMed ID: 9241003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder.
    Versiani M; Cassano G; Perugi G; Benedetti A; Mastalli L; Nardi A; Savino M
    J Clin Psychiatry; 2002 Jan; 63(1):31-7. PubMed ID: 11838623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Canadian multicentre placebo-controlled study of a fixed dose of brofaromine, a reversible selective MAO-A inhibitor, in the treatment of major depression.
    Chouinard G; Saxena BM; Nair NP; Kutcher SP; Bakish D; Bradwejn J; Kennedy SH; Sharma V; Remick RA; Kukha-Mohamad SA
    J Affect Disord; 1994 Oct; 32(2):105-14. PubMed ID: 7829762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.